Curriculum Vitae
Carol Murphy, Director of Research, Biomedical Research Institute, Foundation for Research & Technology Hellas (BRI-FORTH), Ioannina, Greece **Tel: +30 2811 392164** **E-mail: carol_murphy@bri.forth.gr** https://www.bri.forth.gr/en/research/Carol-Murphy.9/
Positions & Employment
2021- **:** Researcher A'. Director of Research at BRI-FORTH, Ioannina, Greece
2003-2021: Researcher B´ at BRI-FORTH, Ioannina, Greece
2015-2017: Senior lecturer, School of Biosciences, University of Birmingham, UK
2001-2003: Researcher C´ at BRI-FORTH, Ioannina, Greece
1997-2001: Researcher in Depart. Biol. Chem., University of Ioannina, Medical School
1996-1997: EU Senior Researcher award for research in University of Ioannina
1993-1996: Postdoctoral researcher at EMBL in the lab of Marino Zerial
1989-1993: Postdoctoral researcher at EMBL in the lab of Ulrich Ruther
1987-1989: Postdoctoral researcher with Frank Gannon, University of Galway, Ireland
Education
1983-1987: Ph.D. in Pharmacology, University College Dublin, Ireland
1978-1982: B.Sc. Pharmacology, University College Dublin, Ireland
Administration
Establishment of confocal microscopy facility at UOI/ BRI-FORTH, Greece (2001)
Establishment/Head of super-resolution microscopy at BRI-FORTH, Greece (2010-2018)
Establishment of hESC and hiPSC unit in BRI-FORTH, Ioannina, Greece (2010- present)
Establishment of hESC and hiPSC unit in University of Birmingham (UoB), UK (2015-2017)
Interdepartmental Committee Member of the Masters in Mol Cell Biol & Biotech, University of Ioannina (2018-2021)
Member of Bioimaging Greece (2017-present)
Director of Birmingham Light Microscopy Facility, UoB, UK (2015-2017)
Imaging Lead for UoB, UK, IMPACT PhD studentship Program (2015-2017)
Lecturer and participating PI in The Wellcome Trust Doctoral Training, MIDAS (2015-2017)
Management Board Member and participating PI in COMPARE network (2015-2017)
Participating PI in "The Midlands Integrative Biosciences Training Partnership" (2015-2017)
Head of ESI committee of BRI, FORTH, Ioannina 2022-2025
Reviewing Activities
Reviewer for many international scientific journals and on editorial board of Scientific Reports.
Reviewer for European Union funding 2019-present

Teaching Activities
1997- present Supervisor of undergraduate, Masters and PhD theses in BRI-FORTH
1997- present Supervisor of PhD students in Biotechnology, Interdepartmental postgraduate program (Medicine, Chemistry and Biological Applications and Technologies)
2015-2017 Undergraduate & Postgraduate Biosciences teaching in University of Birmingham **2015-2017** Lecturer and participating PI in The Wellcome Trust Doctoral Training, MIDAS
2015- 2017 Supervisor of undergraduate, Masters & PhD theses University of Birmingham

2015-present Teacher and Supervisor of Masters project students in the Master's Programme: Molecular Cell Biology and Biotechnology, UOI and BRI-FORTH, Ioannina.
2017-2024 Vice Head of Stem Cell teaching of Master's Programme: Molecular Cell Biology and Biotechnology, UOI and BRI-FORTH, Ioannina. **2024-** Head of Stem Cell teaching of Master's Programme: Molecular Cell Biology and Biotechnology, UOI and BRI-FORTH, Ioannina.
2022-present External collaborator at European University Cyprus
Research Grants
As Principal Investigator or work-package leader
1996-1997 Senior researcher award from the EU: 54,500 ECU.
2000-2002 FP5 ETN project. Membrane-cytoskeleton interactions in intracellular transport and cell morphogenesis. Coordinator: Marino Zerial. Responsible for the Ioannina group: C. Murphy. Total budget: 1.470.000 €. BRI-FORTH: 180,000 €.
2004-2005 GSRT. Applications of light microscopy in biomedical research and diagnosis. Principal investigator: Ch. Boleti, Pasteur Institute, Athens. Responsible for the Ioannina group: C. Murphy. Total budget: 180,000 €. BRI-FORTH: 37,153 €.
2006-2010 GRST PENED 2003/03ED688. Investigation of the role of Rho GTPases in the regulation of the genomic and non-genomic responses of cells to cytokines. Coordinator: C. Stournaras, University of Crete, Responsible for the Ioannina group: C. Murphy. Total budget: 180,000 €. BBRI-FORTH: 44, 625 €
2006-2010 FP6. EndoTrack LSH-2004-1.1.5-2: Tracking the Endocytic Routes of Polypeptide Growth Factor Receptor Complexes and their Modulatory Role on Signalling (EndoTrack). Coordinator: Marino Zerial. Responsible in Ioannina: C. Murphy. Total budget: 10,864,508 €. BRI-FORTH 883,000 €
2007-2013 NSRF. NoisePlus. Mechanisms of Induced Pluripotency:From Transcriptional Noise to Stem Cell Therapies. Coordinator: D. Thanos. Responsible in Ioannina: S. Georgatos. Work package C. Murphy: reprogramming human somatic cells to pluripotency. Total budget: 1.680.000 €. BRI-FORTH 444,500 €
2011-2015 NSRF. StemCycle. Stem Cycle Variations: Comparing the Stem Cell and Cancer Cell Life Cycles. Coodinator: Zoi Lygerou. Responsible in Ioannina: C. Murphy. Budget: 600.000 €. BRI-FORTH 88,500 €.
2011-2015 NSRF. "Remodeling Diabetic and Ischemic Retinal Vasculature Using Progenitor Stem Cells". Acronym: ReVaReSC. Postdoctoral Researcher: Eleni Bagli. Host Institute: BRI-FORTH. Scientific Responsible: C. Murphy, T. Fotsis. Budget: 150.000 €.
2015-2017: **GSRT**. Kripis I: Biology, Biophotonics, and Health: Modern technological approaches and applications in the field of Biology, Photonics and Health. Research program for the development of research institutes. Budget 6.000 €.
2015-2017 University of Birmingham. Role of trafficking and signalling in stem cells. £100.000
2016-2017 The Centre of Membrane Proteins and Receptors (COMPARE) award: Elucidating Activin A/Receptor complex trafficking and signalling: Link to cell differentiation. £25,000. Contract Number: DLABGBI1270.
2019-2021: Human Resource Development, Education and Lifetime Learning. ESPA 2014-2020 co-financing of Greece/European Union. Title: Creation of distinct types of Mural Cells by the differentiation of human pluripotent stem cells and their application in vascularised tissue constructs. Principal Investigator: C. Murphy; Budget 45,500 €.
2020-2023: Unified Action of State Aid for Technology Research Development and Innovation "RESEARCH - CREATE – INNOVATE. ESPA. Title: Development of novel therapeutic strategies against Parkinsons disease. Coordinator: G. Garinis. Responsible in

Ioannina: Murphy/Gkogkas. Budget: 1.000.000 €. BRI-FORTH 200.000 €. Contract number: MIS 5095050
2022-2025: ELIDEK PhD student fellowship. Human vascular organoids as a model system to study retinal diseases. Budget: 32,400 E. Contract number: 06498.
2024-2026 ELIDEK Basic Research Financing Action. Title: Molecular Mechanisms of Vessel Morphogenesis – MorphoVess. Funding Source: Hellenic Foundation for Research and Innovation. Budget: Co-ordinator: Carol Murphy. Collaborating-PI Periklis Papadopoulos. Total budget 400,000E.
2024-2027: ELIDEK PhD student fellowship. Molecular mechanisms of vascular morphogenesis. Budget: 36,000 €.
As key collaborator and/or CO-PI
1998-2001 EPET II, GSRT (97EKBAN2-1.1-20). Early inhibition of sepsis: Development of intervention methods in the molecular mechanism of signal transduction. Coordinator: C. Roussos, Assistant coordinator and principal investigator of the Ioannina team: T. Fotsis. Budget: 880.411 €. BRI-FORTH: 181, 951 €.
2001-2004 FP5 - QLK1-2000-00266. The role of dietary phytoestrogens in the prevention of breast and prostate cancer. Coordinator: Ian Rowland. Principal investigator of the University of Ioannina team: T. Fotsis. Budget: 2.660.430 €. BRI-FORTH: 247,800 €.
2001-2004 FP5 - QLG1-CT-2001-01032. Targeting of angiogenic TGFbeta signalling in cancer and cardiovascular diseases. Coordinator: T. Fotsis. Responsible for the Ioannina team: T. Fotsis. Budget: 1.571.728 €. BRI-FORTH: 284, 196 €.
2003-2007 GSRT, PENED 2001/01ΕΔ585. Signal transduction and intracellular membrane trafficking in endothelial cell. Principal investigator: T. Fotsis. Budget: 132 062 €.
2005-2008 Ministry of Education, **Pythagoras II** programme. The role of lipid rafts and caveolae in thrombosis and angiogenesis. Principal investigator: T. Fotsis. Budget: 50.000 €.
2006-2010 FP6 LSHM-CT-2006-018725. Pulmotension. Pulmonary Hypertension: Functional Genomics and Therapy of Lung Vascular Remodelling. Coordinator: W. Seeger. Responsible in Ioannina: S. Christoforidis. Budget: 11.400.00 €. BRI-FORTH 240.045 €
2007-2013 NSRF. "Education and Lifelong Learning" program "Supporting Postdoctoral Researchers". Title: Bone Regeneration Using Keratin-Based Biomaterials And Mesenchymal Stem Cells. Scientific Responsible: T. Fotsis. Budget: 150.000 €.
2012-2015 NSRF. AdiSC. Title: Role and Mechanisms of Asymmetric Cell Division in Stem Cell Differentiation. Coordinator: T. Fotsis. Budget: 600.000 €. BRI-FORTH: 200,000 €.
2013-2015 NSRF: POM "PIK3CA Oncogenic Mutations in Breast and Colon Cancers: Development of Targeted Anticancer Drugs and Diagnostics". Coordinator: A. Efstratiadis, GD-BRFAA. Responsible for the Ioannina team: T. Fotsis. Budget: 1.962.900 €. BRI-FORTH 189.000 €
2018-2021 Integrated Environmental Management (2.1); Title: Promoting Silver tourism through valorization of MED-diet and wellbeing routes in the CBC area*;* Acronym: Silver wellbeing Funding Source: Hellenic Ministry of Finance and Development & Tourism; Type of Grant: PA 2014-2020/Interreg Greece-Italy/2. Budget: 891.999,12 €. Principal Investigator for BRI-FORTH*:* T. Fotsis; Budget for BRI-FORTH: 158.619,25 €
2020-2022 FORTH SYNERGY GRANT. Title: Modelling neurological disorders using graphene-based neurovascular organoids derived from pluripotent human cells. Funding Source: FORTH Inter-Institutional Interdisciplinary award. Budget: 60,000 €. Co-ordinator: C. Gkogkas, BRI-FORTH, Ioannina. Co-PIs: C. Murphy, BRI-FORTH, Ioannina and G. Deligeorgis, IESL, FORTH, Heraklion, Crete.

Publication record

Number of scientific publications **55.**
Total citations: 5270**.**
H Factor 33**.**
ORCHID ID: 0000-0003-1353-8558.
https://scholar.google.com/citations?hl=el&user=U0ioQy8AAAAJ.

Vrettos E, Kyrkou S, Zoi V, Giannakopoulou M, Chatziathanasiadou M, Kanaki Z, Agalou A, Bistas V-P, Kougioumtzi A, Karampelas T, Diamantis D, **Murphy C**, Beis D, Klinakis A, Tamvakopoulos C, Kyristis A, Lexiou G, Tzakos A: A fluorescent gemcitabine prodrug that follows a nucleoside transporter-independent internalization and bears enhanced therapeutic efficacy with respect to gemcitabine. Chemistry 2024 Jun 28:e202401327. doi: 10.1002/chem.202401327. https://pubmed.ncbi.nlm.nih.gov/38941241/

Karydis-Messinis A, Moschovas D, Markou M, Gkantzou E, Vasileiadis V, Tsirka K, Gioti C, Vasilopoulos KC, Bagli E, **Murphy C**, Salmas CE, Giannakas AE, Hatziloukas E, Stamatis H, Paipetis A, Karakassides MA, Avgeropoulos A, Zafeiropoulos NE: Development, physicochemical characterization and in vitro evaluation of chitosan-fish gelatin-glycerol hydrogel membranes for wound treatment applications. Carbohydrate Polymer Technologies and Applications 6 (2023) 100338. https://www.sciencedirect.com/science/article/pii/S2666893923000592

Karydis-Messinis A, Moschovas D, Markou M, Tsirka K, Gioti C, Bagli E, **Murphy C**, Giannakas AE, Paitetis A, Karakassides MA, Avgeropoulos A, Salmas CE, Zafeiropoulos NE: Hydrogel Membranes from Chitosan-Fish Gelatin-Glycerol for Biomedical Applications: Chondroitin Sulfate Incorporation Effect in Membrane Properties. Gels 2023, 9, 844. https://doi.org/10.3390/gels9110844.

Chalkiadaki K, Statoulla E, Markou M, Bellou S, Bagkli E, Fotsis T, **Murphy C**, Gkogkas C.: Translational control in neurovascular brain development. ***R. Soc. Open Sci.*** 8: 211088. https://doi.org/10.1098/rsos.211088.

Kostopoulou N, Bellou S, Bagli E, Markou M, Kostaras E, Hyvönen M, Kalaidzidis Y, Angelos Papadopoulos A, Chalmantzi V, Kyrkou A, Panopoulou E, Fotsis T, **Murphy C**: Embryonic Stem Cells Are Devoid of Macropinocytosis, a Trafficking Pathway for Activin A in Differentiated Cells. ***J. Cell Sci.*** 2021 Jul 1;134(13):jcs246892. doi: 10.1242/jcs.246892. Epub 2021 Jul 12. https://pubmed.ncbi.nlm.nih.gov/34313314/

Chalmantzi V, Simitzi C, Papadopoulos A, Bagli E, **Murphy C**, Stratakis E, Fotsis T: Culturing human pluripotent stem cells on micropatterned silicon surfaces. In: ***Methods in Molecular Biology***. Springer, New York, NY. doi.org/10.1007/7651_2021_428. Dec. 2021.

Kougioumtzi A , Chatziathanasiadou M , Vrettos EI , Sayyad N, Sakka M, Stathopoulos P, Mantzaris MD , Ganai M, Karpoormath R , Vartholomatos G , Tsikaris V , Lazarides T , **Murphy C,** Tzakos AG: Development of novel GnRH and Tat $^{48\text{-}60}$ based luminescent agents with enhanced cellular uptake and bioimaging properties. ***Dalton Transactions***, issue 26, 2021, https://pubs.rsc.org/en/content/articlelanding/2021/dt/d1dt00060h

Markou M, Kouroupis D, Fotsis T, Bagli E, **Murphy C**. Vascularisation in 3D cell culture. **Basic *Concepts on 3D Cell culture***. Springer. ISBN 978-3-030-66749-8. 2021. https://doi.org/10.1007/978-3-030-66749-8

Vrettos E, Karampelas T., Sayyad N, Kougioumtzi A, Syed N, Crook T, **Murphy C**, Tamvakopoulos C, Tzakos A: Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable "click" oxime bond tethers and preclinical evaluation against prostate cancer. ***Eur. J. Medicinal Chem***. 211(2021)113018. https://pubmed.ncbi.nlm.nih.gov/33223264/

Papadopoulos A, Chalmantzi V, Mikhaylichenko O, Hyvönen M, Stellas D, Kanhere A, Heath J, Cunningham DL, Fotsis T, **Murphy C**: Supporting data on combined transcriptomics and phosphoproteomic analysis of BMP4 signaling in human embryonic stem cells. ***Data in Brief*** 35 (2021) 106844. https://www.sciencedirect.com/science/article/pii/S2352340921001281

Papadopoulos A, Chalmantzi V, Mikhaylichenko O, Hyvönen M, Stellas D, Kanhere A, Heath J, Cunningham DL, Fotsis T, **Murphy C**: Combined transcriptomics and phosphoproteomic

analysis of BMP4 signaling in human embryonic stem cells. ***Stem Cell Res*** 50 (2021) 102133. https://pubmed.ncbi.nlm.nih.gov/33383406/

Markou M, Kouroupis D, Badounas F, Katsouras A, Kyrkou A, Fotsis T, **Murphy C***, Bagli E*. Tissue engineering using vascular organoids from human pluripotent stem cell derived mural cell phenotypes. ***Front Bioeng Biotechnol***, section Tissue Engineering and Regenerative Medicine. 8(2020) article 278, 1-20.* joint corresponding authors. https://pubmed.ncbi.nlm.nih.gov/32363181/

Basagiannis D, Zografou S, **Murphy C**, Fotsis T, Morbidelli L, Ziche M, Bleck C, Mercer J, Christoforidis S. VEGF induces signalling and angiogenesis by directing VEGFR2 internalisation via macropinocytosis. ***J. Cell Sci*** 129 (2016) 4091-4104. https://www.ncbi.nlm.nih.gov/pubmed/27656109

Tsolis K, Bagli E, Kanaki K, Zografou S, Carpentier S, Bei E, Christoforidis S, Zervakis M, **Murphy C**, Fotsis T, Economou A. Proteome changes during transition from human embryonic to vascular progenitor cells. ***J Proteome Res*** 15 (2016) 1995-2007. https://www.ncbi.nlm.nih.gov/pubmed/27146950

Kyrkou A, Stellas D, Syrrou M, Klinakis A, Fotsis T, **Murphy C**: Generation of human induced pluripotent stem cells in defined, feeder-free conditions. ***Stem Cell Res*****,** 17 (2016) 458-460. https://www.sciencedirect.com/science/article/pii/S1873506116300381

Kouroupis D, Kyrkou A, Triantafyllidi E, Katsimpoulas M, Chalepakis G, Goussia A, Georgoulis A, **Murphy C**, Fotsis T: Generation of stem cell-based bioartificial anterior cruciate ligament (ACL) grafts for effective ACL rupture repair. ***Stem Cell Res*** 17 (2016) 448-457. https://www.ncbi.nlm.nih.gov/pubmed/27217303

Karali E, Bellou S, Stellas D, Klinakis A, **Murphy C**, Fotsis T: VEGF signaling, mTOR complexes, and the endoplasmic reticulum: Towards a role of metabolic sensing in the regulation of angiogenesis. ***Mol and Cell Oncol***. 1:3, e964024, https://pubmed.ncbi.nlm.nih.gov/27308350/).

Karali E, Bellou S, Stellas D, Klinakis A, **Murphy C**, Fotsis T: ER mediates induction of endothelial cell survival and angiogenesis by VEGF: PLCg via mTORC1 activates ATF6 and PERK. ***Mol. Cell*** 54 (2014) 559-72. https://www.ncbi.nlm.nih.gov/pubmed/24746698

Kostaras E, Pedersen NM, Stenmark H, Fotsis T, **Murphy C**: SARA and RNF11 at the crossroads of EGFR signalling and trafficking. ***Methods Enzymol*** 535 (2014) 225-47. https://www.ncbi.nlm.nih.gov/pubmed/24377927

Bellou S, Pentheroudakis G, **Murphy C,** Fotsis T: Anti-angiogenesis in cancer therapy: Hercules and Hydra. ***Cancer Lett***. 338 (2013) 291-28. https://www.ncbi.nlm.nih.gov/pubmed/23707856

Kyrkou A, Soufi M, Bahtz R, Ferguson C, Bai M, Parton RG, Hoffmann I, Zerial M, Fotsis T, **Murphy C**: RhoD participates in the regulation of cell-cycle progression and centrosome duplication. ***Oncogene*** 2013, 32:1831-1842. https://www.ncbi.nlm.nih.gov/pubmed/22665057

Kyrkou A, Soufi M, Bahtz R, Ferguson C, Bai M, Parton RG, Hoffmann I, Zerial M, Fotsis T, **Murphy C**: The RhoD to centrosomal duplication. ***Small GTPases*** 2013, 4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747252/

Kostaras E, Sflomos G, Pedersen NM, Stenmark H, Fotsis T, **Murphy C**: SARA and RNF11 interact with each other and ESCRT-0 core proteins and regulate degradative EGFR trafficking. ***Oncogene*** 32 (2013) 5220-32. https://www.ncbi.nlm.nih.gov/pubmed/23222715

Bellou S, Karali E, Bagli E, Al-Maharik N, Morbidelli L, Ziche M, Adlercreutz H, **Murphy C**, Fotsis T: The isoflavone metabolite 6-methoxyequol inhibits angiogenesis and suppresses tumor growth. ***Mol Cancer*** 2012, 11:35. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406996/

Sflomos G, Kostaras E, Panopoulou E, Pappas N, Kyrkou A, Politou AS, Fotsis T, **Murphy C**: ERBIN is a new SARA-interacting protein: competition between SARA and SMAD2 and SMAD3 for binding to ERBIN. ***J Cell Sci*** 2011, 124:3209-3222. https://www.ncbi.nlm.nih.gov/pubmed/21878490

Bellou S, Hink MA, Bagli E, Panopoulou E, Bastiaens PI, **Murphy C**, Fotsis T: VEGF autoregulates its proliferative and migratory ERK1/2 and p38 cascades by enhancing the expression of DUSP1 and DUSP5 phosphatases in endothelial cells. ***Am J Physiol Cell Physiol*** 2009, 297:C1477-1489. https://www.ncbi.nlm.nih.gov/pubmed/19741200

Kardassis D, **Murphy C**, Fotsis T, Moustakas A, Stournaras C: Control of transforming growth factor beta signal transduction by small GTPases. ***FEBS J*** 2009, 276:2947-2965. https://www.ncbi.nlm.nih.gov/pubmed/19490100

Murphy C: Endo-fin-ally a SARA for BMP receptors. ***J Cell Sci*** 2007, 120:1153-1155. https://pubmed.ncbi.nlm.nih.gov/17376961/

Fyhrquist P, Mwasumbi L, Vuorela P, Vuorela H, Hiltunen R, **Murphy C**, Adlercreutz H: Preliminary antiproliferative effects of some species of Terminalia, Combretum and Pteleopsis collected in Tanzania on some human cancer cell lines. ***Fitoterapia*** 2006, 77:358-366. https://www.ncbi.nlm.nih.gov/pubmed/16797142

Papanikolaou A, Papafotika A, **Murphy C**, Papamarcaki T, Tsolas O, Drab M, Kurzchalia TV, Kasper M, Christoforidis S: Cholesterol-dependent lipid assemblies regulate the activity of the ecto-nucleotidase CD39. ***J Biol Chem*** 2005, 280:26406-26414. https://www.ncbi.nlm.nih.gov/pubmed/15890655

Panopoulou E, **Murphy C**, Rasmussen H, Bagli E, Rofstad EK, Fotsis T: Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms. ***Cancer Res*** 2005, 65:1877-1886. https://www.ncbi.nlm.nih.gov/pubmed/15753386

Bagli E, Stefaniotou M, Morbidelli L, Ziche M, Psillas K, **Murphy C**, Fotsis T: Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity. ***Cancer Res*** 2004, 64:7936-7946. https://www.ncbi.nlm.nih.gov/pubmed/15520200

Bagli E., Xagorari A., Papetropoulos A, **Murphy C**, Fotsis T: Angiogenesis in inflammation. ***Autoimmunity reviews*** 2004 3 Suppl 1:S26. https://pubmed.ncbi.nlm.nih.gov/15309776/

Panopoulou E, Gillooly DJ, Wrana JL, Zerial M, Stenmark H, **Murphy C***, Fotsis T*: Early endosomal regulation of Smad-dependent signalling in endothelial cells. ***J Biol Chem*** 2002, 277:18046-18052. * joint last authors. https://www.ncbi.nlm.nih.gov/pubmed/11877415

Karetsou Z, Kretsovali A, **Murphy C**, Tsolas O, Papamarcaki T: Prothymosin alpha interacts with the CREB-binding protein and potentiates transcription. ***EMBO Rep*** 2002, 3:361-366. https://www.ncbi.nlm.nih.gov/pubmed/11897665

Hatzi E, **Murphy C**, Zoephel A, Rasmussen H, Morbidelli L, Ahorn H, Kunisada K, Tontsch U, Klenk M, Yamauchi-Takihara K, et al.: N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth. ***Oncogene*** 2002, 21:3552-3561. https://www.ncbi.nlm.nih.gov/pubmed/12032857

Hatzi E, **Murphy C**, Zoephel A, Ahorn H, Tontsch U, Bamberger AM, Yamauchi-Takihara K, Schweigerer L, Fotsis T: N-myc oncogene overexpression down-regulates leukemia inhibitory factor in neuroblastoma. ***Eur J Biochem*** 2002, 269:3732-3741. https://www.ncbi.nlm.nih.gov/pubmed/12153570

Murphy C, Saffrich R, Olivo-Marin JC, Giner A, Ansorge W, Fotsis T, Zerial M: Dual function of rhoD in vesicular movement and cell motility. ***Eur J Cell Biol*** 2001, 80:391-398. https://www.ncbi.nlm.nih.gov/pubmed/11484930

Hatzi E, Breit S, Zoephel A, Ashman K, Tontsch U, Ahorn H, **Murphy C**, Schweigerer L, Fotsis T: MYCN oncogene and angiogenesis: down-regulation of endothelial growth inhibitors in human neuroblastoma cells. Purification, structural, and functional characterization. ***Adv Exp Med Biol*** 2000, 476:239-248. https://pubmed.ncbi.nlm.nih.gov/10949669/

Pappas P, Stephanou P, Sotiropoulou M, **Murphy C**, Salminen L, Marselos M: Effects of tamoxifen and toremifene on ALDH1 and ALDH3 in human retinal pigment epithelial cells and rat liver. ***Adv Exp Med Biol*** 1999, 463:151-158. https://pubmed.ncbi.nlm.nih.gov/10352680/

McBride HM, Rybin V, **Murphy C**, Giner A, Teasdale R, Zerial M: Oligomeric complexes link Rab5 effectors with NSF and drive membrane fusion via interactions between EEA1 and syntaxin 13. ***Cell*** 1999, 98:377-386. https://pubmed.ncbi.nlm.nih.gov/10458612/

Zacchi P, Stenmark H, Parton RG, Orioli D, Lim F, Giner A, Mellman I, Zerial M, **Murphy C**: Rab17 regulates membrane trafficking through apical recycling endosomes in polarized epithelial cells. ***J Cell Biol*** 1998, 140:1039-1053. https://pubmed.ncbi.nlm.nih.gov/9490718/

Simonsen A, Lippe R, Christoforidis S, Gaullier JM, Brech A, Callaghan J, Toh BH, **Murphy C**, Zerial M, Stenmark H: EEA1 links PI(3)K function to Rab5 regulation of endosome fusion. ***Nature*** 1998, 394:494-498. https://pubmed.ncbi.nlm.nih.gov/9697774/

Murphy C, Zacchi P, Parton RG, Zerial M, Lim F: HSV infection of polarized epithelial cells on filter supports: implications for transport assays and protein localization. ***Eur J Cell Biol*** 1997, 72:278-281.https://pubmed.ncbi.nlm.nih.gov/9084990/

Zuniga Mejia Borja A, **Murphy C**, Zeller R: AltFGF-2, a novel ER-associated FGF-2 protein isoform: its embryonic distribution and functional analysis during neural tube development. ***Dev Biol*** 1996, 180:680-692. https://pubmed.ncbi.nlm.nih.gov/8954736/

Murphy C, Saffrich R, Grummt M, Gournier H, Rybin V, Rubino M, Auvinen P, Lutcke A, Parton RG, Zerial M: Endosome dynamics regulated by a Rho protein. ***Nature*** 1996, 384:427-432. https://pubmed.ncbi.nlm.nih.gov/8945468/

Kretschmer C*, **Murphy C***, Biesinger B, Beckers J, Fickenscher H, Kirchner T, Fleckenstein B, Ruther U: A Herpes saimiri oncogene causing peripheral T-cell lymphoma in transgenic mice. ***Oncogene*** 1996, 12:1609-1616.* joint first authors. https://pubmed.ncbi.nlm.nih.gov/8622880/

Murphy C, Zerial M: Expression of Rab proteins during mouse embryonic development. ***Methods Enzymol*** 1995, 257:324-332. https://pubmed.ncbi.nlm.nih.gov/8583936/

Murphy C, Beckers J, Ruther U: Regulation of the human C-reactive protein gene in transgenic mice. ***J Biol Chem*** 1995, 270:704-708. https://pubmed.ncbi.nlm.nih.gov/7822299/

Murphy C, Kretschmer C, Biesinger B, Beckers J, Jung J, Desrosiers RC, Muller-Hermelink HK, Fleckenstein BW, Ruther U: Epithelial tumours induced by a herpesvirus oncogene in transgenic mice. ***Oncogene*** 1994, 9:221-226. https://pubmed.ncbi.nlm.nih.gov/8302583/

Lutcke A, Parton RG, **Murphy C**, Olkkonen VM, Dupree P, Valencia A, Simons K, Zerial M: Cloning and subcellular localization of novel rab proteins reveals polarized and cell type-specific expression. ***J Cell Sci*** 1994, 107 (Pt 12):3437-3448. https://pubmed.ncbi.nlm.nih.gov/7706395/

Fotsis T, **Murphy C**, Gannon F: Nucleotide sequence of the bovine insulin-like growth factor 1 (IGF-1) and its IGF-1A precursor. ***Nucleic Acids Res*** 1990, 18:676. https://pubmed.ncbi.nlm.nih.gov/2308858/

Murphy C, Fotsis T, Pantzar P, Adlercreutz H, Martin F: Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). ***J Steroid Biochem Mol Biol*** 1987, 26:547-555. https://pubmed.ncbi.nlm.nih.gov/3586671/

Murphy C, Fotsis T, Pantzar P, Adlercreutz H, Martin F: Analysis of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen levels in cytosol and KCl-nuclear extracts of breast tumours from tamoxifen treated patients by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). ***J Steroid Biochem Mol Biol*** 1987, 28:609-618. https://pubmed.ncbi.nlm.nih.gov/3695512/

Murphy C, Fotsis T, Adlercreutz H, Martin F: Analysis of tamoxifen and 4-hydroxytamoxifen levels in immature rat uterine cytoplasm and KCl-nuclear extracts by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). ***J Steroid Biochem Mol Biol*** 1987, 28:289-299. https://pubmed.ncbi.nlm.nih.gov/3657151/